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Abstract	(248	words)	
Molecular	imaging	using	radiopharmaceuticals	has	a	clear	role	in	visualizing	the	presence	
and	extent	of	tumour	at	diagnosis	and	monitoring	response	to	therapy.	Such	imaging	
provides	prognostic	and	predictive	information	relevant	to	management,	e.g.	by	
quantifying	active	tumour	mass	using	PET/CT.	As	these	techniques	require	only	
pharmacologically	inactive	doses,	age	and	potential	frailty	are	generally	not	important.	This	
may	be	different	for	therapy	involving	radionuclides	because	the	radiation	can	impact	
normal	bodily	function	(e.g.	myelosuppression).	Since	the	introduction	of	Iodine-131	as	a	
targeted	therapy	in	thyroid	cancer,	several	radiopharmaceuticals	have	been	widely	used.	
These	include	antibodies	and	peptides	targeting	specific	epitopes	on	cancer	cells.	Among	
therapeutic	bone	seeking	agents,	radium-223	(223Ra)	stands	out	since	it	results	in	survival	
gains	in	patients	with	castration-resistant	prostate	cancer	and	symptomatic	bone	
metastases.	The	therapeutic	use	of	radiopharmaceuticals	in	older	cancer	patients	
specifically	has	received	little	attention.	In	elderly	prostate	cancer	patients,	there	may	be	
advantages	in	radionuclides’	ease	of	use	and	relative	lack	of	toxicity	compared	with	
cytotoxic	and	cytostatic	drugs.	When	using	radionuclide	therapies,	close	co-ordination	
between	oncology	and	nuclear	medicine	is	needed	to	ensure	safe	and	effective	use.	Bone	
marrow	reserve	has	to	be	considered.	Since	most	radiopharmaceuticals	are	cleared	renally,	
dose	adjustment	may	be	required	in	the	elderly.	However,	compared	with	younger	patients	
there	is	less,	if	any,	concern	about	adverse	long-term	radiation	effects	such	as	radiation-
induced	second	cancers.	Issues	regarding	the	safety	of	medical	staff,	care	givers	and	the	
wider	environment	can	be	managed	by	current	precautions.		
Keywords:	radionuclide	imaging,	radionuclide	therapy,	elderly,	comorbidities,	prostate	
cancer,	molecular	imaging,	radium-223	
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Introduction	
Diagnostic	radiopharmaceuticals	are	generally	pharmacologically	inactive	and	given	only	in	
the	relatively	small	doses	needed	for	imaging.	Such	agents	are	considered	to	have	no	
measurable	pharmacodynamic	impact.[1]	For	these	reasons	there	is	little	concern	about	
specific	toxicity	problems	arising	with	age,	although	the	practicalities	of	imaging	older	
patients	need	to	be	considered.	In	contrast,	with	therapeutic	radiopharmaceuticals,	the	
desired	clinical	benefit	arises	from	the	effects	of	radiation	on	the	tumour,	and	courses	of	
treatment	may	involve	frequent	administration.	In	this	context,	both	age-related	changes	
in	tissues,	such	as	bone	marrow,	and	questions	of	altered	drug	clearance	arise.		
A	Task	Force	of	the	International	Society	of	Geriatric	Oncology	(SIOG)	considered	practical	
recommendations	on	the	use	of	radiopharmaceuticals,	both	diagnostic	and	therapeutic,	in	
older	cancer	patients.	This	increasingly	important	topic	has	not	previously	been	reviewed	
from	the	perspective	of	older	patients.	Such	a	perspective	is	important	since	physiological	
reserves	typically	decline	with	age,	many	older	patients	have	significant	comorbidities,	and	
there	is	increased	risk	of	interactions	with	drugs	taken	for	concomitant	disease.	[2,3]		
Systemically	administered	therapeutic	radiopharmaceuticals	are	used	in	thyroid	cancer	(an	
area	in	which	there	is	more	than	fifty	years	of	experience),	in	neuroendocrine	tumours,	in	
non-Hodgkin’s	lymphoma	and	in	myeloproliferative	diseases.	However,	these	tumours	are	
relatively	infrequent,	even	in	the	elderly.		
The	most	common	tumours	(lung,	colorectal,	breast	and	prostate),	show	a	steeply	rising	
incidence	and	mortality	with	increasing	age	(Figure	1).[4]	Among	these	four	tumours,	the	
risk	of	skeletal	involvement	is	high	in	three:	in	advanced	stages	of	the	disease,	bone	
metastases	are	present	in	47-85%	of	breast	cancer	patients,	32-60%	of	those	with	lung	
cancer,	and	33-85%	of	prostate	cancer	patients.[5]	Given	recent	increased	interest	in	
radionuclides	in	patients	with	bone	metastases	from	castration	resistant	prostate	cancer	
(CRPC),	and	since	more	than	90%	of	them	have	skeletal	metastases,[6]	discussion	of	the	
therapeutic	use	of	radiopharmaceuticals	focused	on	this	area.		
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Figure	1	(A)	Incidence	and	(B)	mortality	of	the	three	most	frequent	cancers	in	Europe	in	
men	and	women	according	to	age	(Data	from	[http://globocan.iarc.fr	GLOBOCAN	2012,	
last	accessed	on	September	2014,	21],	IARC®)	
	
	
The	general	principles	underlying	radionuclide	use	in	the	elderly	are	likely	to	be	similar	to	
those	in	younger	patients.	However,	elderly	patients	have	been	under-represented	in	
clinical	trials,	despite	the	fact	that	the	majority	of	cancers	–	and	hence	of	treatment	–	is	in	
precisely	these	patients.	Hence,	as	in	most	areas	of	oncology,	specific	data	on	the	efficacy	
and	toxicity	of	radionuclides	in	these	populations	are	limited.		
Task	Force	members	conducted	literature	searches	in	their	areas	of	expertise.	We	make	no	
attempt	to	formally	assign	levels	of	evidence	to	recommendations.	They	should	be	
considered	those	of	an	expert	group,	and	the	basis	for	further	discussion.	The	
recommendation	that	more	elderly	patients	should	be	included	in	trials	is	an	obvious	
starting	point.		
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Age	and	frailty:	general	considerations		
While	chronological	aging	is	uniform	and	relentless,	biological	aging	is	not.	The	main	
relevant	factors	are:	i)	functional	losses,	including	those	relating	to	cognition;	ii)	the	effects	
of	declining	physiological	reserves	on	resistance	to	toxicity	and	on	drug	handling;	and	iii)	
the	implications	of	comorbidities	and	associated	polypharmacy.	
The	broad	concept	of	frailty,	defined	as	vulnerability	in	the	face	of	a	stressor,	is	of	interest	
to	clinicians	assessing	the	likely	side	effects	of	therapy.[7]	Functional	status	and	the	
presence	of	comorbidities	are	the	most	readily	available	guides	to	patients	who	are	
especially	vulnerable	to	adverse	effects	of	treatment.		
Means	of	assessing	the	overall	fitness	of	elderly	patients	and	the	likely	toxicity	of	
chemotherapy	have	been	developed.[2,8,9]	Although	they	have	not	been	assessed	in	the	
context	of	radiopharmaceuticals,	such	tools	may	help	predict	any	toxicity		in	elderly	
patients.		
In	the	setting	of	prostate	cancer	specifically,	a	recent	SIOG	Task	Force	[3]	has	advocated	
initial	screening	for	cognitive	impairment,	to	establish	patient	competence	in	making	
decisions,	followed	by	brief	evaluation	of	health	status	using	the	validated	G8	screening	
tool.	Abnormal	scores	on	the	G8	should	lead	to	a	simplified	geriatric	assessment	that	
evaluates	comorbid	conditions,	dependence,	and	nutritional	status	(by	estimation	of	
weight	loss).		
Also	in	the	prostate	cancer	setting,	the	potential	importance	of	comorbidities	is	illustrated	
by	the	trial	in	which	D’Amico	et	al	randomized	206	men	to	radiotherapy	(RT)	alone	or	RT	
plus	androgen	suppression.	[10]	For	the	group	as	a	whole,	combined	treatment	was	
associated	with	significantly	reduced	all-cause	mortality	(30	vs.	44	deaths,	p=0.01).	
However,	among	men	with	moderate	or	severe	comorbidity,	there	was	a	trend	in	the	
opposite	direction	with	more	deaths	in	the	RT	plus	androgen	suppression	group	than	in	
those	treated	with	RT	alone	(19	vs.	13	deaths,	p=0.08).	While	acknowledging	that	they	
derive	from	a	subgroup	analysis,	such	data	make	a	strong	case	for	distinct	trials	to	be	
conducted	in	patients	with	comorbidities.		
Most	radiopharmaceutical	studies	do	not	include	specific	measures	of	comorbidity,	frailty	
or	functional	loss.	In	their	absence,	the	potential	impact	of	such	agents	on	less	fit	patients	
must	be	extrapolated	from	the	healthier	patients	who	were	enrolled,	or	from	studies	of	
other	agents	which	did	include	less	fit	patients.		
	
7	
Radiopharmaceuticals	in	imaging	
Diagnosis	and	staging	
The	availability	of	information	from	radionuclide	imaging	contributes	greatly	to	
personalized	cancer	treatment.	Here,	we	do	not	seek	to	compare	the	merits	of	different	
imaging	techniques,	but	consider	them	from	the	perspective	of	the	elderly.	
In	older	Medicare	patients	(mean	age	73	years),	analysis	of	registry	data	from	more	than	
twenty	thousand	imaging	studies	demonstrated	that	having	information	from	fluorine-18-
FDG	(18F-FDG)	positron	emission	tomography	computed	tomography	(PET-CT)	led	to	a	
major	change	in	management	in	30-40%	of	cases	and	a	minor	change	in	another	10-
30%.[11]	The	report	covered	the	role	of	imaging	in	diagnosis,	staging,	restaging,		and	
investigation	for	suspected	recurrence	and	monitoring	response	to	therapy.	It	concluded	
that	physicians	frequently	change	their	intended	management	of	elderly	cancer	patients	on	
the	basis	of	PET	scans,	and	that	this	applies	across	the	range	of	its	uses.	However,	it	is	
notable	that	only	5%	of	patients	in	the	study	were	aged	85	years	or	more.		
Other	important	applications	include	guiding	and	selecting	biopsy	sites,	identifying	tumours	
in	patients	with	rising	markers,	guiding	radiation	therapy,	and	distinguishing	tumour	
recurrence	or	residual	tumour	from	post	therapy	changes	(such	as	fibrosis	and	necrosis)	on	
CT.		
In	several	tumours,	imaging	with	a	variety	of	radiopharmaceuticals	is	an	integral	part	of	
diagnosis.	Although	extremely	rare,	adverse	allergic	reactions	have	been	reported	with	18F-
FDG.[12-14]	Overall,	however,	diagnostic	nuclear	medicine	is	associated	with	an	
exceptionally	low	risk	of	toxicity	since,	at	the	dose	administered,	the	agents	are	not	
pharmacodynamically	active.	In	a	prospective	questionnaire	study	conducted	over	four	
years	covering	80,000	radiopharmaceutical	administrations	for	PET	in	22	participating	
institutions,	Silberstein	found	no	reports	of	adverse	reactions.[15]	In	an	earlier	five-year	
prospective	study	in	18	institutions,	only	18	adverse	reactions	were	recorded	in	more	than	
780,000	radiopharmaceutical	administrations.[16]	Of	these	reactions,	ten	were	rashes.	
None	of	the	patients	involved	required	hospitalization	or	had	significant	sequelae.		
Use	of	diagnostic	radiopharmaceuticals	does	not	require	assessment	of	renal	insufficiency;	
and	although	diabetic	patients	should	have	a	glucose	level	that	is	well	controlled	on	the	day	
of	the	18FDG	PET,	co-medication	with	metformin	is	not	a	potential	problem.	In	both	cases,	
this	situation	is	different	from	that	with	computed	tomography	involving	contrast	media.	
In	general,	no	clinically	relevant	issues	arise	relating	to	the	particular	vulnerability	of	elderly	
patients,	nor	to	the	increased	risk	of	drug	interaction	or	toxicities	related	to	comorbidities.	
Furthermore,	compared	with	children	and	young	adults,	the	long-term	risks	for	radiation-
induced	second	cancers	associated	with	radiation	exposure	due	to	diagnostic	medical	
procedures	are	unlikely	to	be	relevant	in	elderly	patients	with	more	limited	life	expectancy.		
However,	there	are	certain	practical	considerations	relating,	for	example,	to	technetium-
99m-bisphosphonate	bone	scintigraphy,	which	is	still	the	standard	method	of	staging	in	
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advanced	prostate	cancer.[17,18]	Although	safe,	the	length	of	time	that	may	be	required	
for	scanning	can	be	difficult	for	older	patients,	especially	for	those	with	musculoskeletal	
problems	who	find	prolonged	immobility	uncomfortable	and	even	painful.	In	frail	elderly	
patients,	it	is	worth	considering	an	increase	in	the	dose	of	isotope	administered	to	allow	
shortening	of	the	scanning	time,	thereby	minimizing	patient	discomfort.		
	
Prognosis	and	treatment	monitoring		
Prognosis	is	of	concern	with	all	patients	but	is	particularly	relevant	to	the	elderly	in	whom	
expected	benefits	and	toxicity	must	be	balanced	in	the	light	of	concomitant	disease	and	
competing	causes	of	death.	Information	from	radionuclide	scanning	can	contribute	
considerably	to	management	decisions.	If	used	appropriately,	it	may	avoid	the	need	for	
other	investigations,	as	well	as	unnecessary	treatment.	Such	an	outcome	is	desirable	for	
reasons	of	patient	comfort,	quality	of	life	and	cost.		
The	quantification	of	overall	tumour	load	and,	more	importantly,	of	biologically	aggressive	
tumour	is	relevant	to	a	variety	of	cancers.	However,	whether	or	not	it	is	a	predictor	of	poor	
outcome	depends	on	the	tumour	type	and	on	the	treatments	available.	In	colorectal	and	
squamous	cell	lung	cancer,	a	high	standardized	uptake	volume	(SUVmax)	suggests	poor	
prognosis.[19]	Quantitative	analysis	of	FDG	PET	has	value	in	predicting	relapse-free	and	
overall	survival	independently	of	TNM	staging	in	non-small	cell	lung.[20].	Also,	in	
lymphoma	FDG-PET	has	become	a	standard	imaging	method	for	therapy	monitoring,	
providing	prognostic	and	predictive	information.	A	computer	programme	to	aid	such	
quantification	is	being	developed	to	calculate	its	predictive	value.	[21]		
FDG	PET	can	identify	previously	unknown	second	primary	tumours	(which	are	present	in	
about	1-2%	of	patients)	or	distant	metastases	(Figure	2),	as	in	head	and	neck	cancer	
cancer.[22]	Knowing	their	presence	may	influence	the	timing	and	aggressiveness	with	
which	the	initial	or	primary	cancer	is	treated.		
FDG	PET	also	allows	identification	of	patients	who	fail	to	respond	to	initial	cycles	of	
neoadjuvant	chemotherapy.	Such	techniques	seem	especially	useful	in	cancers	including	
those	of	the	head	and	neck,	oesophagus,	bladder	and	lung.[23-27]		
Other	radiopharmaceuticals	are	relevant	to	a	specific	cancer-related	process.	Use	of	
fluorine-18-FLT,	a	marker	for	tumour	cell	proliferation,	can	be	valuable	e.g.	in	monitoring	
the	treatment	of	lymphoma	or	the	effectiveness	of	radiotherapy	and	in	adjusting	the	
treated	volume.	[28,29]	
	Such	adaptive	radiation	therapy	allows	treatment	to	be	confined	to	a	smaller	area	at	
increased	dose	when	a	tumour	has	been	reduced	in	size,	or	stopped	or	changed	in	those	
who	are	clearly	not	responding.[30]		
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Figure	2			A	69-year	old	patient	with	biochemical	relapse	from	prostate	cancer	(Gleason	7,	
PSA	3	ng/mL)	showing	a	single	site	of	bone	metastasis	on	the	right	ischium	with	18F-
choline	PET	not	visible	by	bone	scintigraphy.	The	patient	received	isolated	radiation	
therapy	and	the	PSA	decreased	to	<0.05	ng/mL).	He	has	been	relapse-free	for	24	months.		
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Table	1.		Concerns	about	radiopharmaceuticals	in	diagnosis,	monitoring	and	therapy	and	
their	potential	relevance	to	the	elderly	cancer	patient		
	
In	castration	resistant	prostate	cancer	(CRPC)	patients	on	systemic	treatment,	current	
ESMO	guidelines	recommend	regular	imaging	to	monitor	disease	response	or	progression,	
although	their	recommendation	is	supported	by	a	relatively	low	level	of	evidence	(V).[31]	
At	the	time	of	writing,	the	latest	EANM	guidelines	were	still	in	preparation.	FDG	PET	CT	
scan	is	not	recommended	for	prostate	cancer	except	for	aggressive	form	of	disease,	while	
bone	scan	using	99mTc-labeled-diphosphonates	is	still	standard.[18]	
Techniques	such	as	sodium	18F	PET-CT	may	prove	valuable	in	relation	to	223Ra	
treatment.[32]	At	present,	a	standard	bone	scan	is	still	routine	to	select	eligible	patients.	In	
the	individual	patient,	and	in	the	absence	of	trial	evidence,	practice	in	relation	to	imaging	
should	be	guided	by	factors	such	as	the	goal	of	treatment,	PSA	increase	and	velocity,	and	
clinical	suspicion.		
Newer	agents	targeting	the	prostate	specific	membrane	antigen	(PSMA)	are	being	
developed	and	used	clinically	based	on	68Ga	and	18F	radioisotopes	and	have	already	been	
shown	superior	to	choline-labelled	tracers.	These	are	likely	to	develop	further	and	play	a	
significant	role	in	CRPC.	[33,34]		
In	Europe,	Ga-68-PSMA-11	PET/CT	(PSMA	PET/CT)	is	increasingly	used	and	provides	
sensitivity	and	specificity	superior	to	that	of	F-18-FCH,	although	it	is	not	yet	approved	by	
the	EMA.	The	technique	has	potential	as	a	means	of	triaging	patients	to	be	treated	by	Ra-
223	or	Lu-177-PSMA.	[35]	11C-	or	18F-choline	radiopharmaceuticals	have	proved	useful	in	
	 	 	
Diagnosis	and	
monitoring,	
including	for	
relapse	
Therapy	 	
Age-related	alterations	in	
pharmacokinetics	or	
pharmacodynamics	resulting	in	
reduced	efficacy	or	increased	
toxicity	
For	FDG,	check	
glucose	levels	
Minor	for	223Ra,	which	is	excreted	
predominantly	in	faeces.	But	renal	
function	is	relevant	for	other	
therapeutic	radionuclides	
	
Interaction	with	drugs	being	
taken	for	comorbid	conditions	
None	 	Minor,	though	certain	beta-blockers,	
for	example,	decrease	MIBG	targeting	
	
Effects	on	reproductive	
function,	foetal	toxicity	and	
breast	feeding	
Not	applicable	 Not	applicable	 	
Risk	of	long-term	radiation	
toxicities	such	as	induction	of	
treatment-related	solid	and	
haematological	cancers	
None	 Less	concern	in	elderly	populations	than	
in	younger	patients	
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detecting	biochemical	relapse	in	prostate	cancer	patients.[33]	An	example	is	shown	in	
Figure	2.		
	
Therapeutic	radiopharmaceuticals	
Age-related	dose	adjustment	is	generally	not	required.	If	necessary,	anaemia	should	be	
corrected	as	part	of	general	supportive	care.	There	are	no	guidelines	specific	to	the	need	
for	transfusions	in	the	haematopoietic	support	of	patients	being	treated	with	
radiopharmaceuticals.		Transfusion	should	therefore	be	used	at	the	physician’s	discretion.		
The	use	of	phosphorous-32	(32P)	in	refractory	myeloproliferative	diseases	such	as	
polycythemia	vera	and	essential	thrombocythemia	should	also	be	acknowledged.	Although	
overshadowed	by	recent	developments,32P	is	well	tolerated	and	can	be	particularly	helpful	
in	older	patients	in	whom	one	or	two	doses	provide	adequate	disease	control.	In	short,	
established	drugs	may	work	well,	and	perhaps	especially	so	in	patients	with	limited	life	
expectancy.		
In	solid	tumour	oncology,	the	archetypical	targeted	radiopharmaceutical	is	131I	for	the	
treatment	of	differentiated	thyroid	cancer	following	thyroidectomy.	The	safety	and	efficacy	
of	this	treatment	in	both	adjuvant	and	metastatic	settings,	are	well	established	and	
thoroughly	discussed	elsewhere.[36]	In	relation	to	the	elderly,	it	is	worth	noting	that	it	may	
be	preferable	to	raise	TSH	levels	by	injection	of	recombinant	TSH	(rTSH)	(Thyrogen®)	pre-
treatment	rather	than	by	thyroid	hormone	withdrawal.	This	avoids	a	prolonged	period	of	
hypothyroidism	and	the	associated	risks	of	depression	and	reduced	metabolism	and	
activity,	which	may	be	especially	harmful	in	the	elderly.	However,	this	approach	is	not	
approved	in	all	countries,	and	the	number	of	rTSH	administrations	may	be	restricted	to	two	
in	addition	to	the	initial	treatment.	
Although	this	paper	relates	mostly	to	solid	tumours,	radioimmunotherapy	contributes	to	
the	treatment	of	haematological	malignancies.	Most	attention	has	focused	on	CD20-
positive	non-Hodgkin’s	lymphoma	(NHL).		Although	effective	in	subgroups	of	patients,	this	
treatment	option	is	not	widely	used.	In	their	2005	review,	[37]	Rao	et	al.	concluded	that	
these	agents	are	well	tolerated	in	elderly	NHL	patients,	even	though	marrow	involvement	is	
common.	Caution	is	required	if	more	than	25%	marrow	is	involved,	in	case	of	prior	marrow-
ablative	therapy	or	hypocellular	bone	marrow	(<	15%).	
There	is	also	evidence	for	the	efficacy	of	90Y	resin	microspheres	in	the	radioembolization	of	
patients	with	advanced	hepatocellular	carcinoma.[38]	This	may	have	particular	relevance	in	
elderly	patients	needing	to	avoid	chemotherapy.	In	a	pan-European	series	of	325	patients	
treated	by	this	method,	the	mean	age	was	65	years	(range	22-87).	However,	the	
administration	of	90Y	microspheres	and	of	131I-lipiodol	is	invasive	since	it	involves	selective	
hepatic	artery	injection.	Shunting	to	the	lungs,	normal	liver	and/or	stomach	may	result	in	
clinically	significant	short-term	radiation	burden	(inducing	pneumonitis,	hepatitis	or	
stomach	ulceration).	This	may	be	particularly	relevant	in	older	patients	with	reduced	
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pulmonary	or	liver	function	and	potential	additional	gastric	toxicity	arising	from	
concomitant	medication.		
An	interesting	application	of	radioembolization	is	in	the	treatment	of	early-stage	disease	
with	a	curative	intent,	given	that	90%	of	90Y-treated	tumours	less	than	3cm	and	two-thirds	
of	tumours	of	3-5cm	show	complete	pathologic	necrosis	(so-called	radiation	
segmentectomy).[39]	Additionally,	it	has	been	observed	that	treatment	of	a	lobe	results	in	
atrophy	of	that	lobe	and	hypertrophy	of	the	contralateral	one,	a	characteristic	that	may	aid	
in	resection.[40]			
When	considering	a	patient	for	radioembolization,	the	tumor	stage,	liver	function,	renal	
function,	performance	status,	α-fetoprotein	level,	coagulation	parameters,	and	goals	of	
treatment	must	be	taken	into	consideration.	This	is	most	reliably	achieved	through	a	
multidisciplinary	board.		
Patients	with	poor	hepatic	reserve	are	less	likely	to	tolerate	a	whole	liver	treatment.	Other	
patients	at	high	risk	include	those	with	disease	affecting	>50%	of	the	liver,	albumin	less	
than	30	g/L	(3	mg/dL),	or	bilirubin	greater	than	34.2	µmol/L	(2	mg/dL).[41]	Patients	with	
impaired	pulmonary	status	should	also	be	examined	carefully,	because	a	significant	lung	
shunt	fraction	is	more	likely	to	cause	life-threatening	radiation	pneumonitis.	Prior	external	
beam	radiation	therapy	is	also	considered	a	contraindication.	
Radiopharmaceuticals	are	also	being	used	with	good	palliative	effect	in	metastatic	or	
unresectable	neuroendocrine	tumours.	These	agents	target	either	the	noradrenaline	
transporter	(in	the	case	of	131I-MIBG)	or	somatostatin	receptor	subtypes	overexpressed	on	
tumour	cells	using	90Y	linked	to	the	somatostatin	analogues	octreotide	or	octreotate	(90Y-
DOTATOC	and	-DOTATATE).	With	the	latter	agents,	which	accumulate	in	the	renal	cortex,	
renal	toxicity	is	a	concern,	as	is	thrombocytopenia	due	to	bone	marrow	toxicity.	However,	a	
study	of	more	than	five	hundred	patients	treated	with	DOTATATE	found	few	adverse	
events.[42]	A	recent	review	concluded	that,	while	mild	haematological	toxicity	with	the	
two	agents	was	common,	renal	toxicity	was	rare.[43]	However,	the	mean	age	of	the	
patients		was	57	years	(range	not	given),	so	the	impact	on	older,	frailer	patients	has	not	
been	established.		
	
Bone	seeking	agents	
In	relation	to	more	prevalent	cancers,	the	frequent	occurrence	of	osseous	metastases	in	
advanced	disease	has	focused	attention	on	the	potential	of	bone	metastasis-seeking	
radiopharmaceuticals.	Of	these,	89strontium,	and	153samarium-EDTMP	emit	b–	particles	
(electrons)	with	a	few	millimetre	range	and	a	relatively	limited	biological	effect.	(Table	3.)	
The	alpha	emitter	223Ra,	on	the	other	hand,	has	effects	that	are	confined	to	a	few	cell	
diameters	(<0.1	mm)	but	are	more	powerful.	Whereas	a	b–	(electron)	emitter	may	require	
more	than	a	thousand	DNA	hits	to	achieve	cell	kill,	this	effect	is	achieved	with	only	1-4	hits	
from	an	alpha	emitter.	The	fact	that	radiation	damage	is	confined	to	the	40-100µm	area	
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immediately	surrounding	223Ra	molecules,	rather	than	up	to	12	mm	with	b–	emitters,	
suggests	a	reduced	likelihood	of	adverse	effects	on	nearby	bone	marrow.		
While	89strontium	and	153samarium-EDTMP	have	proven	valuable	in	the	relief	of	pain	due	to	
bone	metastases	in	mCRPC,	223Ra	has	been	shown	in	robust	phase	III	studies	to	result	in	
improved	overall	survival.	Other	radiopharmaceuticals	have	not	been	shown	to	have	this	
effect.[44]		Hence	223Ra	is	a	therapy	to	be	considered	alongside	abiraterone	or	
enzalutamide.	In	addition	to	its	role	in	prolonging	survival,	the	agent	may	provide	effective	
pain	relief.		
Although	important	for	all	patients,	patient	preference	is	particularly	relevant	to	the	elderly	
in	whom	quality	of	life	(QoL)	is	pre-eminent.	In	this	context,	it	is	worth	noting	that	
strontium-89	has	been	associated	with	well-maintained		QoL	in	metastatic	CRPC,	and	223Ra	
with	improved	QoL	relative	to	placebo	in	the	same	setting.	[45,46]	There	is	a	general	
reluctance	to	undergo	chemotherapy	if	there	are	less	toxic	alternatives,	and	older	patients	
may	trade	slightly	reduced	efficacy	for	higher	quality	of	life	or	less	risk	of	adverse	events.	In	
metastatic	CRPC,	the	almost	simultaneous	advent	of	life-prolonging	androgen	receptor	
targeting	agents,	immunotherapy,	a	novel	taxane	and	a	new	radiopharmaceutical	poses	
acute	questions	about	the	optimal	sequencing	and	potential	combination	of	
treatments.[31]		
Use	of	therapeutic	radiopharmaceuticals	such	as	223Ra	in	the	elderly,	as	in	younger	patients,	
is	clearly	feasible.	Given	patients’	more	limited	life	expectancy,	long-term	toxicities,	notably	
the	risk	of	inducing	a	second	cancer,	are	of	less	(if	any)	concern.	This	raises	the	question	of	
whether	their	use	in	elderly	patients	should	be	governed	by	regulations	less	stringent	than	
those	applicable	to	the	treatment	of	younger	adults.	
Risk	of	short	term	toxicities	arising	from	damage	to	the	kidneys	and	bone	marrow	may	be	
exacerbated	by	reduced	renal	and	marrow	reserves.	However,	since	treatment	is	
fractionated	over	six	cycles	one	month	apart,	radiation	exposure	on	each	occasion	is	one	
sixth	or	less	of	the	maximum	tolerated	dose.	Even	so,	there	is	the	possibility	that	prior	
treatment	with	radiopharmaceuticals	may	mean	that	subsequent	chemotherapy	is	less	well	
tolerated,	raising	issues	of	optimal	sequencing.	Age,	especially	in	combination	with	poor	PS,	
is	considered	a	risk	factor	for	febrile	neutropenia.[47]		
In	the	ALSYMPCA	trial,	600	patients	with	CRPC	were	treated	with	223Ra	and	toxicities	were	
generally	mild.[48]	The	most	frequent	reported	side	effects,	occurring	in	more	than	10%	of	
patients,	were	anemia,	thrombocytopenia,	constipation,	nausea,	diarrhoea,	vomiting,	
fatigue,	weight	loss,	anorexia,	bone	pain	and	peripheral	oedema.		
Grade	3-4	anemia	was	reported	in	13%	of	223Ra-treated	patients,	but	this	rate	was	not	
significantly	different	from	that	with	placebo.	Anemia	seemed	related	to	extensive	disease	
rather	than	treatment;	and	patients	experiencing	anemia	did	not	suffer	more	than	others	
from	side	effects.	Grade	3	or	4		thrombocytopenia	occurred	in	6%	of		223Ra-treated	
patients.	One	death	from	thrombocytopenia	was	reported.	The	fall	in	platelets	seemed	
related	to	treatment,	since	it	was	less	frequent	with	placebo,	occurring	in	only	2%	of	
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patients.	However,	the	6%	rate	seen	in	patients	receiving	223Ra	was	still	low.		Grade	3-4	
neutropenia	occurred	in	3%	of	treated	patients.		
It	should	be	noted	that	certain	toxicities	associated	with	223Ra	are	of	particular	concern	in	
the	elderly.	They	are	at	greater	risk	in	the	case	of	diarrhoea,	a	known	side	effect,	leading	to	
dehydration	and	possible	kidney	damage	and	other	sequelae	such	as	confusion	and	
electrolyte	disturbance;	anaemia	is	less	well-tolerated;	and	thrombopenia	may	be	a	
particular	problem	in	patients	on	anticoagulants.		
The	EMA-approved	label	for	223Ra	indicates	that	there	are	limited	data	on	patients	with	
moderate	renal	impairment,	and	no	data	on	severe	impairment	or	end-stage	renal	disease;	
and	safety	has	not	been	studied	in	patients	with	hepatic	impairment.	However,	since	223Ra	
is	not	cleared	through	the	kidneys,	nor	metabolised	by	the	liver	or	eliminated	via	the	bile,	
renal	or	hepatic	impairment	are	not	expected	to	affect	its	pharmacokinetics.				
	
Radiopharmaceuticals	in	prostate	cancer	
Prospective	phase	III	data	in	metastatic	CRPC	support	the	first-line	use	of	docetaxel,	
enzalutamide	and	abiraterone	(all	of	which	significantly	extend	OS)	and	of	sipuleucel-T	and	
223Ra.	These	latter	agents	also	extend	OS	but	their	pivotal	trials	also	included	patients	who	
had	had	prior	chemotherapy	(though	in	the	case	of	the	sipuleucel-T	trial,	they	amounted	
only	to	15%).[49-53]	Second	line,	there	are	prospective	data	only	for	patients	who	had	had	
prior	docetaxel.		
With	regard	to	223Ra,	the	ALYSMPCA	trial	included	patients	with	CRPC	metastatic	to	
bone.[48]	Fifty-seven	percent	had	received	prior	docetaxel.	The	chemo-naïve	subgroup	was	
not	clearly	defined	and	included	patients	unfit	for	chemotherapy,	those	unwilling	to	
undergo	it,	and	those	without	access	to	it.	Patients	with	visceral	metastases	and	bulky	
lymph	node	disease	were	excluded.	
Table	2	summarises	current	recommendations	relevant	to	use	of	radiopharmaceuticals	in	
mCRPC.		
Of	note,	the	2016	European	Association	of	Urology	(EAU)	guidelines	on	prostate	cancer	
contain	a	section	specific	to	management	of	the	disease	in	elderly	men,	which	should	be	
undertaken	by	a	multidisciplinary	team.[54].	In	accord	with	the	SIOG	working	group	on	
prostate	cancer,[55]	the	EAU	recommends	use	of	the	G8	screening	tool	for	initial	
assessment	of	health	status,	followed	when	appropriate	by	full,	specialist	geriatric	
assessment	to	determine	the	reversibility	of	any	impairments.	Subsequent	management	
should	be	based	on	an	elderly	patient’s	individual	health	status.		
The	role	of	newly	developed	agents	for	mCRPC	has	not	been	well	defined	in	elderly	men	
specifically.	However,	the	relative	ease	of	administering	223Ra	(i.v.	every	four	weeks)	and	
the	fact	that	it	seems	generally	well	tolerated	and	does	not	interact	with	co-medication	
may	make	it	a	good	option	in	elderly	patients,	especially	those	with	multiple	co-morbidities	
(Figure	3).	It	would	be	of	great	help	to	randomize	the	new	CRPC	agents	against	each	other	
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in	a	trial	specifically	designed	to	include	elderly	patients	and	with	a	focus	on	quality	of	life	
and	patient-reported	outcomes.	
	
Figure	3			Example	of	bone	scintigraphic	response	in	a	72-year	old	patient	with	metastatic	
castration-resistant	prostate	cancer	and	multiple	bone	metastases	(A)	in	the	skull,	right	
hemi-jaw,	left	shoulder,	ribs,	thoracic	and	lumbar	spine	and	(B)	after	6-courses	of	223Ra	
over	6	months.	
	
	
16	
Table	2			Summary	of	current	recommendations	relevant	to	use	of	radiopharmaceuticals	
in	metastatic	castration-resistant	prostate	cancer	(mCRPC)	
Source	 Setting	 Recommendations	 Evidence	
level		
Grade	
Reference	
ESMO	
	 	
First	line	in	mCRPC	
	
	
	
	
	
Second	line	(post	docetaxel)	
Docetaxel	
For	asymptomatic	or	mildly	symptomatic	
disease:	abiraterone,	enzalutamide		
or	sipuleucel-T	
For	bone	predominant,	symptomatic	disease	
without	visceral	metastases:	223Ra	
	
Abiraterone,	cabazitaxel,	enzalutamide,	and	
223Ra	(in	those	without	visceral	disease)	
I	A	
I	A		
	
	II	B	
	I	A		
	
	
I	A	
Parker	et	
al	2015	
[31]	
European	
Association	
of	Urology	
	
	
	
Candidates	for	cytotoxic	
therapy	
Relapse	following	docetaxel	
	
	
No	clear-cut	recommendation	can	be	made	
for	the	most	effective	drug	for	secondary	
treatment	(ie	hormone	therapy	or	
chemotherapy)		
		
Offer	docetaxel	75	mg/m2	every	3	weeks.		
	Offer	further	life	prolonging	treatment	
options,	which	include	cabazitaxel,	
abiraterone,	enzalutamide	and	radium-223.		
Base	second-line	treatment	decisions	on	pre-
treatment	performance	status,	comorbidities	
and	extent	of	disease.		
	
	
3	A	
		
	
	
1a	A	
		
1a	A	
	
B	
Mottet	et	
al,	2016	
[54]	
	 Non-specific	management	 In	painful	bone	metastases,	palliate	early	
using	radionuclides,	external	beam	
radiotherapy	and	analgesics		
1a	B	 	
NCCN	 Initial	therapy:	
													no	visceral	metastases	
	
													visceral	metastases	
	
	
Subsequent	systemic	therapy:	
	
Abiraterone,	docetaxel,	enzalutamide,	or	
223Ra	(for	symptomatic	bone	mets);	or	clinical	
trial;	or	secondary	hormone	therapy	
Docetaxel,	enzalutamide;	
or	abiraterone,	or	mitoxantrone	(if	not	
candidate	for	docetaxel);	clinical	trial;	or	
secondary	hormone	therapy	
	
For	patients	with	prior	exposure	to	
	
Cat.	1	
	
Cat.	1		
	
	
Cat.	1	
NCCN.org	
v2.2016	
[56]	
17	
								no	visceral	metastases	
	
	
										
visceral	metastases	
docetaxel,	223Ra	is	among	the	10	options	
(including	docetaxel	re-challenge	and	best	
supportive	care);	for	patients	with	prior	
enzalutamide	or	abiraterone,	223Ra	is	among	
8	options	
	
223Ra	not	among	the	options	
American	
Urological	
Association	
Symptoms	related	to	bony	
metastases;	no	known	visceral	
disease	
															no	prior	docetaxel	
	
	
														prior	docetaxel	
	
	
223Ra	an	option	in	patients	with	good	PS;	
also	an	option	in	selected	poor	PS	patients	
when	PS	is	directly	related	to	symptoms	
related	to	bone	mets.		
223Ra	an	option	in	good	PS	patients	
	
		
STANDARD	
EXPERT	
OPINION	
	
STANDARD		
AUA	
2015[57]		
American	
Society	of	
Clinical	
Oncology	
	
No	prior	docetaxel	
	
	
Prior	docetaxel	
Continue	androgen	deprivation	indefinitely	
Offer	abiraterone,	enzalutamide	or	223Ra;	
may	also	offer	docetaxel/prednisone	
accompanied	by	discussion	of	toxicity	risk;	
and	sipuleucel-T	if	no	or	minimal	symptoms.	
	May	offer	cabazitaxel	with	toxicity	
discussion;	or	mitoxantrone	with	discussion	
of	limited	benefit	and	toxicity	risk.	
	
Benefit	of	
223Ra	
moderate;	
harm	low;	
evidence	
strong;	
recommend-
ation	strong	
Basch	E	et	
al		2014	
[58]	
PS:	performance	status	NCCN:	National	Comprehensive	Cancer	Network	
	
When	any	of	these	recommendations	go	beyond	existing	data,	they	are	phrased	with	
caution,	as	is	appropriate	given	the	absence	of	comparative	studies.	Use	of	
radiopharmaceuticals	is	cited	as	one	of	several	options,	but	223Ra	is	linked	to	the	presence	
of	symptomatic	bone	metastases	and	the	absence	of	visceral	involvement	–	which	implies	
that	clinicians	must	look	for	such	disease.	Although	PS	is	a	factor	in	the	AUA	management	
plan,	none	of	the	recommendations	is	age-specific	or	accounts	for	age-associated	factors	
such	as	comorbidities	and	frailty.		
The	NCCN	suggests	that	estimation	of	remaining	life	expectancy	is	critical	to	informed	
decision	making	about	disease	management	and	recommends	that	clinicians	consult	the	
actuarial	life	tables.	For	patients	judged	to	be	in	the	best	quartile	of	overall	health,	50%	
should	be	added	to	the	given	life	expectancy	for	age;	and	for	patients	in	the	poorest	
quartile,	50%	should	be	deducted.		
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Guidance	from	trial	data	related	to	age		
The	pivotal	trials	mentioned	above	differ	in	their	inclusion	and	exclusion	criteria	with	
respect	to	factors	such	as	PS,	the	presence	of	visceral	metastases	and	whether	or	not	
patients	had	received	prior	docetaxel.	Within	the	recommendations,	there	is	a	certain	
amount	of	age-related	evidence	to	guide	choice	of	an	agent	for	older	patients.	With	
docetaxel,	the	OS	benefit	in	patients	aged	75	years	and	in	patients	aged	65	years	and	above	
is	similar	to	that	in	the	wider	population	studied.[59]	Forty	percent	of	elderly	patients	had	
grade	3-4	AEs,	and	there	was	a	greater	need	for	dose	reduction.		
In	the	pivotal,	placebo-controlled	enzalutamide	trial,	35%	of	enrolled	patients	were	aged	75	
or	more.[60]	The	PFS	and	OS	benefits	of	treatment	were	significant	both	in	this	age	group	
and	in	younger	patients.	Similarly,	in	the	pivotal	trial	versus	mitoxantrone,	the	OS	benefit	of	
cabazitaxel	was	similar	across	prespecified	subgroups,	including	patients	aged	65	and	
above.		
Table	3	shows	the	physical	characteristics	and	clinical	outcomes	of	currently	available	
radiopharmaceuticals.		
	
Table	3.		Physical	and	clinical	characteristics	of	therapeutic	radiopharmaceuticals	in	
current	use	for	prostate	cancer	
	
Agent	 T	½		
Days	
Tissue	
penetration	
max	
(mean)	mm	
Standard	
dose		
	
Efficacy	 Toxicity	
89strontium	 50.5	 5.5	(2.4)	 148	MBq	 Pain	reduction:	
33%	CR;	time	to	
response	4-28	
days;	no	OS	
benefit	
Leucopenia	in	20-80%	and	
thrombocytopenia	in	30-80%	(both	
reversible);	minimal	anaemia	
153samarium	 1.9	 2.5	(0.6)	 37	MBq/kg	 Pain	relief	in	
83%	of	pts,	
complete	in	31-
38%	no	OS	
benefit	
Reversible	leucopenia	in	40-50%	of	pts	
and	thrombocytopenia	in	20-42%	
223radium	 11.4	 <0.1	 	50kBq/kg	 Significantly	
increased	OS	
compared	with	
control	group	
(14.9	vs.	11.	3	
months);	
significantly	
longer	time	to	
first	skeletal	
event	(15.6	vs.	
9.8	months)		
Grade	3-4	anemia		in	13%	of	223Ra-
treated	patients	was	not	significantly	
different	from	placebo.	Gr	3-4	
thrombocytopenia	in	6%	of	treated	
patients	versus	2%	with	placebo.	
Occasional	cases	of	fatigue,	nausea	
and	loose	stools;	but	toxicities	in	
general	are	comparable	with	placebo.		
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In	the	ALSYMPCA	trial	in	men	with	CRPC	and	symptomatic	bone	metastases,	the	median	
age	of	patients	enrolled	was	71,	and	28%	were	aged	over	75	years.[48]	The	mean	
haemoglobin	level	of	patients	included	was	12.2g/dl,	which	seems	higher	than	expected	in	
routine	practice	for	this	patient	population;	and	no	data	are	given	about	comorbidities	or	
geriatric	functional	assessment.		
It	is	not	clear	how	many	of	the	patients	who	did	not	have	prior	docetaxel	had	refused	
chemotherapy,	how	many	were	judged	unfit	for	chemotherapy,	and	how	many	had	no	
access	to	it.	It	is	therefore	difficult	to	judge	the	efficacy	and	safety	of	this	treatment	in	
elderly	patients.	In	the	poorer	PS	group,	the	0.73	HR	for	OS	was	in	the	same	positive	
direction	as	for	the	population	as	a	whole.	However,	the	benefit	of	treatment	did	not	
achieve	statistical	significance;	and,	as	with	any	subgroup	analysis,	this	finding	can	be	
considered	only	as	hypothesis	generating.	
	
Protection	and	safety	when	using	therapeutic	radiopharmaceuticals	
Protecting	hospital	staff,	the	general	public	and	the	environment	from	unnecessary	
exposure	to	radiation	is	a	major	concern	in	radiopharmaceutical	diagnostics	and	therapy.	
Relevant	regulations	differ	considerably	from	one	country	to	another.	For	example,	there	
have	been	concerns	in	Germany	about	the	possibility	of	exhaled	radon.	Swiss	patients	given	
223Ra	have	to	accept	that	cremation	must	be	postponed	(or	burial	used	instead)	if	they	die	
within	seven	days	of	its	administration.	Nuclear	medicine	physicians	and	technicians	need	
to	check	which	are	applicable	to	the	place	they	practice.	
Elderly	patients	are	more	likely	than	their	younger	counterparts	to	require	urgent	surgery	
for	conditions	unrelated	to	cancer.	In	any	patient	with	bone	metastases,	there	is	the	
possibility	that	fracture	or	spinal	cord	compression	will	necessitate	surgical	intervention.	
More	generally,	a	patient’s	overall	functional	status	–	especially	possible	incontinence	–	is	
an	age-related	factor	that	is	clearly	relevant	to	radioprotection.		
Appropriate	radioprotection	advice	should	be	available	to	hospital	staff	when	required	in	
managing	a	patient	recently	treated	with	a	radiopharmaceutical	(protective	eyeware	for	
operating	theatre	staff	and	double	pairs	of	gloves,	for	example,	would	be	appropriate).	
	
Discussion	and	conclusions	
The	use	of	radiopharmaceuticals	to	accurately	image	the	spread	of	disease	is	of	proven	
value.	They	are	also	likely	to	be	useful	in	quantifying	the	burden	of	metabolically	active	
tumour,	which	will	further	aid	in	personalising	treatment.	In	relation	to	the	elderly	patient	
with	significant	comorbidities	and	limited	life	expectancy,	the	prognostic	information	such	
imaging	could	provide	would	be	particularly	valuable	in	enabling	them	to	avoid	
unnecessary	treatment	and	preserve	quality	of	life.		
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When	attempting	to	make	recommendations	for	the	elderly,	it	is	striking	to	find	that	so	few	
older	patients	have	been	entered	into	pivotal	clinical	trials,	even	of	targeted	anti-cancer	
agents.[61]	In	an	ideal	world,	the	proportion	of	elderly	patients	included	in	a	trial	would	
match	the	proportion	of	those	with	the	disease.	In	the	real	world,	there	may	be	a	case	for	
providing	companies	with	incentives	to	enrol	such	patients	in	key	studies,	or	with	requiring	
them	to	conduct	trials	specifically	in	the	elderly,	those	who	have	comorbidities	and	those	
who	are	frailer.[62]		
The	fifty-year	history	of	131I	in	thyroid	tumours	should	give	us	confidence	that	
radiopharmaceuticals	can	safely	be	used	in	the	treatment	of	cancer	in	a	wide	range	of	
patients.	However,	with	each	new	radioisotope	and	indication	come	unquantified	risks.	
This	applies	both	to	the	patients	treated	and	to	the	staff	treating	them.	In	the	elderly	
prostate	cancer	patient	with	symptomatic	bone	metastases	and	a	life	expectancy	of	under	
five	years,	it	is	very	unlikely	that	long-term	effects	of	radiation	exposure	will	become	
apparent.	In	a	young	woman	with	breast	cancer,	this	is	not	necessarily	the	case.	However,	
both	kinds	of	patient	must	be	assessed	for	the	risk	of	short-term	toxic	effects,	for	example	
to	bone	marrow	or	the	kidney.	And	staff	administering	radiopharmaceuticals	are	
understandably	concerned	about	the	potential	long-term	impact	of	radiation	on	their	
general	health	and	wellbeing,	including	fertility.	Both	patients	and	staff	should	be	fully	
informed	and	given	written	information	about	risks.		
Bone-seeking	radiopharmaceuticals	have	no	role	in	preventing	the	development	of	visceral	
metastases.	While	the	risk	of	such	involvement	is	initially	low	in	prostate	cancer,	almost	
50%	of	patients	develop	them	at	later	stages	of	disease,	and,	with	the	prolongation	of	
survival	following	the	introduction	of	new	drugs,	this	proportion	is	likely	to	increase.	[63]	
Studies	to	assess	whether	the	use	or	radiopharmaceuticals	in	combination	with	chemo-	and	
other	systemic	therapies	will	increase	clinical	benefit	with	acceptable	additional	toxicity	are	
now	being	conducted.		
Since	the	relative	costs	of	individual	agents	vary	greatly	from	one	health	system	and	
country	to	another,	it	is	difficult	to	include	such	factors	in	clinical	recommendations.	
However,	the	availability	and	expense	of	different	agents	are	clearly	relevant	to	the	making	
of	therapeutic	decisions	in	the	everyday	management	of	the	elderly,	as	with	all	cancer	
patients.	
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Table	4			Take-home	messages	
• Include	more	elderly	patients	in	pivotal	clinical	trials;	this	applies	also	to	targeted	
anti-cancer	agents	
The	under-representation	of	elderly	cancer	patients	in	pivotal	clinical	trials	restricts	
our	ability	to	tailor	management	to	their	specific	circumstances	(comorbidities	and	
fraility)	
• Diagnostic	radiopharmaceuticals	are	not	an	issue	of	particular	concern	in	elderly	
patients,	even	in	the	presence	of	vulnerability	
Consider	increasing	isotope	dose	activity	to	decrease	scan	time	and	so	minimize	
patient	discomfort	
• Therapeutic	radiopharmaceuticals	in	elderly	patients	with	hormone-resistant	
prostate	cancer	and	symptomatic	metastases	are	safe	but	require	
o assessment	of	short-term	toxic	effects	on	bone	marrow	and		
o adequate	information	to	be	given	to	patients,	family	members	
and	care	staff	
• More	studies	are	needed	on	the	combination	of	therapeutic	radiopharmaceuticals	
with	chemo-	and/or	other	systemic	therapies	to	determine	if	increased	clinical	
benefit	can	be	achieved	with	acceptable	additional	toxicity	
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